Feeds:
Posts
Comments

Archive for the ‘Lilly’ Category

*****
TODAY’S NEWS

Valeant goes for the niches. Deliberately.

Eli Lilly still chopping positions – Eli Lilly and Co. plans to cut 200 sales and marketing support jobs Friday in its U.S. biomedicine group, with more than half of those cuts taking place in Indianapolis, a company spokesman confirmed Thursday. The cuts are the latest wave of the drugmaker’s previously announced plans to chop 5,500 jobs worldwide by the end of 2011 in response to financial pressuresmore

InVentiv to be acquired by private equity firm.

Bayer gets new type of contraceptive approved – The Food and Drug Administration approved Natazia, which is the first in the U.S. to deliver doses of its two female hormones at four times during the drug’s 28-day treatment cycle, the agency said today in a statementmore. But then, what about that mystery recall of Yaz last year – who knew??

I don’t know, Mr Harper (Forbes) – isn’t it more accurate to say that an application has been rejected, rather than that a drug has been rejected, when a Complete Response Letter is issued? The semantics are important.

RECOMMENDED

Down – like, seriously depressed? Get Some Help.

PLUS

More doctors giving drug reps the cold shoulder. And, sunlit leaves in dark shadow (pic).

JUST FOR FUN

Astonishing stuff – A Showcase of 3-D Street Art Paintings. How do people do this?

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

Coming up on May 11th: BDI’s Social Communications & Healthcare event – half day session in NYC with Case Studies and Roundtables (I’ll be leading one of the roundtables). Top speakers from J&J, Pfizer, and more! These are always great networking and learning events. Hope to see you there!

For more information, including registration, please click here to visit the event website. Use promo code IMPACT for a discounted rate of $155.

TODAY’S NEWS

Lilly in an Indy pullback.

Taking another look at medical uses for hallucinogens. Timothy Leary would be proud!

Byetta (once-weekly) and possible cancer risks. Frankly, I have a bit of problem with this sort of stuff. When you pump rats with mega-doses of just about anything, what do you expect? Eternal life?

If you need a Monday morning dose of super-sized, complex words in a cloud of oncology verbiage, this one’s for you. Otherwise, nothing to see here…

RECOMMENDED

Selling Skills – We can recommend best-in-class partners and programs for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Letting Go.

JUST FOR FUN

Visual treat – Steel Giants floating on a blanket of Fog.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Alpharma/King to pay big fine – American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain. Alpharma is now a wholly-owned subsidiary of Bristol, Tenn.-based King Pharmaceuticals Incmore

Don’t go buying Lilly drugs on the street corner – In a departure from the recent M.O. of in-transit drug cargo thefts, emboldened thieves hit Eli Lilly’s 70,000-square-foot east coast distribution facility in Enfield, CT. And they hit it hard: $70 million to $75 million worth of Prozac, Cymbalta and Zyprexa–enough to fill a large trailer, according to press reportsmore

More and more scripts going unfilled.

Preventing diabetes with drugs – very hard questions being asked.

The interesting background story on new drug Xiaflex (NY Times) – It took half a century. But a tiny drug maker on Long Island has finally found a potentially lucrative use for its only medicine: straightening clenched fingers. And, if research proves successful, treating a condition that causes bent penisesmore

RECOMMENDED

Talent Selection/Talent Management – Validated tools and processes to assess employee talent. We’ve got that.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Salesperson as rebel (Business Week) – but can this mentality even remotely work within pharma?

JUST FOR FUN

Reflection photography – 44 impressive examples. Eye candy.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

TriCor = placebo? Not good news for Abbott - A popular triglyceride-lowering drug that has been taken by millions of Americans failed to prevent heart disease in a big federal study being presented todaymore

FDA to Eli Lilly/Amylin on once-weekly Byetta: No.

OSI to Astellas: No.

FDA to Plavix (from BMS and Sanofi): black-box warning.

RECOMMENDED

Negotiations Training/Presentation Training – Your sales people, account managers, leaders and executives need  to grow in these skills. We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

You’ve heard all about reach and frequency. How about each and recently? And, when it comes to Pharma and Social Media: One or Many?

JUST FOR FUN

Dogs filmed at 1,000 frames per second. You’ve never seen dogs jump quite like this before.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

*****

TODAY’S NEWS

Big approval news for Gilead Sciences Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food and Drug Administration cleared sales of the medicine, given the brand name Cayston, the company said today in a statement. Outside advisers to the FDA backed the product’s safety and effectiveness in a 15-2 vote on Dec. 10more

What is the future of “personalized medicine”? Probably, it’ll look a lot like this (encouraging story from NY Times). Plus, in a cooperative effort, Eli Lilly, Merck and Pfizer have formed an independent, not-for-profit company Asian Cancer Research Group (ACRG) to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asiamore

Of course, in this industry, there is often a mix of good news and bad – and “bad” usually means bad behavior by people who love dollars above sense: lack of openness at AZ?; secret tapes and GSK (plus, a “fixer” who spiked research?); research fraud by rogue doc; kickbacks and J&J; risk of depression assessment and Eli Lilly (are you alive? then you’re at risk!!!). Reminds me of some prior posts on the Gold-in Rule

Novartis looking to expand even more at East Hanover campus. Including themed food venues!

RECOMMENDED

Marketing Training – Looking for resources for training brand marketing professionals? We know the providers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.

PLUS

I’m feeling much safer now. FDA finally comes out against “ear candling“! Next up, perhaps – a prohibition of USB-to-nasal-passage uploads??

JUST FOR FUN

Delightful (and BIG) pictures from Vancouver Olympics. Love the colors in the very first one. From Boston.com’s very nice The Big Picture section.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

FDA warning letters to Lilly, Bayer, Amylin, Cephalon.

Wow: ARBs for hypertension reducing Alzheimer’s symptoms? – Drugs commonly used to lower blood pressure, sold by AstraZeneca Plc, Sanofi-Aventis SA and Merck & Co., may also reduce the risk of developing Alzheimer’s disease. Researchers from Boston University analyzed the medical records of more than 800,000 U.S. veterans and found those taking angiotensin receptor blockers were up to 24 percent less likely to develop dementia than patients on other medications. Patients already diagnosed with Alzheimer’s disease were half as likely to be admitted to a nursing home and had a 17 percent reduced risk of dying if they were taking the medicationsmore

FTC wants to put a stop to the “pay-to-delay” deals – Jon Leibowitz will hold a press conference today to ask Congress to include a provision in the health care reform bill to end deals in which brand-name drugmakers offer payments or other inducments to generic rivals to delay copycat versions of best-selling medsmore

RECOMMENDED

Product/Therapeutic training development (pharma/biotech/devices). Live training, modules, eLearning – we’ve got the expertise and customer-centric approach in our vendor/partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media, Opportunity, and Serendipity – my guest post on the Hive Awards blog.

JUST FOR FUN

Visual awesomeness. Photo of Martian dune field. Quite spectacular!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

See the newly-re-launched Impactiviti Collection e-newsletter! Here’s a link to the on-line sample; you can sign up to receive the Connection (~every two weeks) right here.

TODAY’S NEWS

Pfizer and Wyeth to sell off some Animal Health assets to Boehringer-Ingelheim.

Speaking of B-I, here’s a presentation from them on how they successfully use Twitter. Boehringer is one of the more engaged and interactive companies in the space.

Eli Lilly‘s Alimta improves survival for lung cancer.

RECOMMENDED

District/Regional Manager development workshops. If you’re looking to developing your FLMs in a variety of skills, our best-in-class training providers can customize a program for your needs. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Podcast today discussing latest social media in pharma developments, and upcoming Digital Pharma conference in October. Archived here.

JUST FOR FUN

Is it candy? Or medicine? This poster‘s both funny and a bit…scary.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Where I’ll be next week: Sept. 23-24 – MedAdNews PharmaMed Marketing and Media conference, Princeton, NJ. I’ll be speaking on social media opportunities in pharma, and live-blogging.

TODAY’S NEWS

Novartis sees positive results with experimental COPD drug – Swiss drugmaker Novartis said a respiratory medicine improved lung function and significantly reduced breathlessness in a late stage trial. The outcome added to data suggesting QAB149 will challenge blockbusters like Pfizer’s Spiriva and GlaxoSmithKline‘s Advair, giving Novartis an edge in one of the industry’s most lucrative therapeutic areasmore

J&J/Elan deal getting the once-over to try to appease Biogen - Elan, the Irish domiciled biotech company, will receive $115m less than previously agreed from Johnson & Johnson as part of a revised investment deal designed to salvage a pivotal partnership with Biogen Idecmore

Eli Lilly to do massive re-org – Eli Lilly announced that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that’s expected to net the firm reduce $1 billion in costs by 2011. This move will drop the company’s headcount from approximately 40,500 to 35,000. The company hasn’t revealed where the cuts will come from or how many will be real layoffs and how many will simply be reduced positionsmore More from the Lilly CEO here.

New MRSA drug approved – Theravance Inc. and partner Astellas Pharma won FDA approval for their superbug-fighting drug telavancin, which will bring the South San Francisco company a $20 million milestone paymentmore

GSK will have to share Paxil e-mails in birth defect lawsuit.

An interesting analysis of Qnexa (the next weight-loss drug?) by Jim Edwards. Is it too good??

Metformin as a treatment for cancer??

RECOMMENDED

Change. Innovation. Do you need to provide training to your team on change management? Or bringing about effective innovation? The Impactiviti Partner network has great vendor/partners who can help you with these offerings. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

A new site for accessing medical device/pharmaceutical sales positions listed by recruiters: MedPharmReps.

JUST FOR FUN

Do you know anyone with their internal organs reversed? Turns out that there are such folks…maybe even you!

We had a wonderful and restful vacation last week, touring through Massachusetts, Maine, New Hampshire, and Vermont. I uploaded some pictures along the way on my “twitpic” account – here’s one sample:

VermontWine

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Femara keeps breast cancer at bay better than tamoxifen – Novartis AG’s Femara prevented breast cancer from returning regardless of whether women took the drug for five years or switched to a less expensive, generic medication two years into the treatment, a study found. Initial results from the trial involving 4,922 patients found women who took Femara for five years were less likely to have the cancer return, particularly in another spot, than those who took only the generic drug tamoxifenmore

Eli Lilly stops development of bone loss drug – Eli Lilly & Co. halted development of its experimental bone drug arzoxifene, once one of its most promising new treatments, after a study found it didn’t prevent nonspinal fractures and increased blood clots and hot flashesmore

More good news for Avastin – Swiss-based Roche Holding AG said on Tuesday a study had showed its drug Avastin increased life expectancy for women with breast cancer without the disease getting worse, when used alongside common chemotherapiesmore

GSK and Genmab - Arzerra results not so good – A clinical trial of Arzerra, a drug being developed by Danish biotechnology company Genmab and backed by Glaxo, had proven disappointing, Genmab management said yesterday. Among patients with non-Hodgkin’s lymphoma that were given a high dose of the drug, only 10pc saw their cancer shrink – a response rate far lower than expectedmore

Eyedrops for Claritin and Zyrtec. Neither of which contain the ingredients in Claritin or Zyrtec. Hmmmm….

RECOMMENDED

Oncology training – some of my training partners specialize in training for oncology groups – product training, account management training, advanced selling skills, and much more. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for some brainstorming and vendor recommendations to boost the performance of your oncology sales team.

PLUS

The No Drone Zone. Can you create a company of just top performers? See what Netflix has done (StickyFigure blog post).

JUST FOR FUN

I’ve got a baaaad feeling about this

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

NEWS

One of Eli Lilly‘s patents on Gemzar invalidated; may shave off 3 years of exclusivity – the method of use patent for its cancer drug Gemzar was invalidated by a federal court in Michigan, the drugmaker said today…more

Merck‘s Gardasil vaccine safe overall, though some questions about promotional practices – two researchers at Columbia College of Physicians and Surgeons reported that Merck wrongly got professional medical groups to help promote its vaccine through speakers who didn’t provide balanced recommendations concerning Gardasil’s risks and benefits…more

Canadian study: GSK‘s Avandia does have more heart risks than Takeda‘s Actos – Researchers analyzed prescription data for 39,736 patients ages 66 and older who were enrolled in the Ontario Public Drug Benefit Program and began taking Avandia or Actos from April 2002 to March 2008. During the six-year study, 6.9 percent of patients on Avandia died or were hospitalized for a heart attack or heart failure, compared with 5.3 percent of those on Actos…more

So – what about Key Account Management? Some thoughts from Pharmaceutical Executive.

RECOMMENDED

Are you looking at social media applications, either in-house (enterprise communications) or outward-facing (marketing communications)? I can help, with strategy consultation and vendor/provider recommendations. Contact me (stevew at impactiviti dot com) and let’s talk! (In the meantime, download my free e-book, Getting Started with Social Networking)

ePharma Review: My take on Novartis Oncology’s CML Earth. A very good start here for a social media platform; still room for improvement.

PLUS

Thought-provoking: People don’t Leave Organizations – They Leave Managers. AND – from my StickyFigure blog – Ask the Right Questions. Where you start determines where you end up…

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers